title: The Pharmacokinetics of Pregabalin in Breast Milk, Plasma, and Urine of Healthy Postpartum Women.
abstract: Limited data exist on the presence of pregabalin in human breast milk of nursing mothers.
  
  
  
  This study aimed to determine pregabalin concentrations in breast milk, estimate the infant daily pregabalin dose from nursing mothers, and evaluate pregabalin pharmacokinetic data in lactating women (≥ 12 weeks postpartum).
  
  
  
  In this multiple-dose, open-label, pharmacokinetic study, 4 doses of pregabalin 150 mg were administered orally at 12-hour intervals. Urine, blood, and breast milk samples were collected up to 12, 24, and 48 hours, respectively, following the fourth dose. Pharmacokinetic parameters were estimated using noncompartmental methods. Adverse events were monitored throughout.
  
  
  
  Ten healthy lactating women (age 24-37 years) received pregabalin. Geometric mean pregabalin Cmaxssand AUCτ values in breast milk were approximately 53% and 76%, respectively, of those for plasma. The mean amount of pregabalin in breast milk recovered in a 24-hour period after the last dose was 574 μg (range, 270-1720 μg), which is approximately 0.2% of the administered daily maternal dose of 300 mg. The estimated average daily infant dose of pregabalin from breast milk was 0.31 mg/kg/day, which would be approximately 7% (23% coefficient of variation) of the body weight normalized maternal dose. Approximately 89% of the dose administered was recovered in urine. Renal clearance averaged 68.2 mL/min. Adverse events were of mild or moderate severity.
  
  
  
  Lactation appears to have had little influence on pregabalin pharmacokinetics. Overall, the estimated dose of pregabalin in breastfed children of women receiving pregabalin is low. Pregabalin was well tolerated in lactating women.
  
  
  
  The authors declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: Peter A. Lockwood, Lynne Pauer, Joseph M. Scavone, Maud Allard, Laure Mendes da Costa, Tanja Alebic-Kolbah, Anna Plotka, Christine W. Alvey, and Marci L. Chew were all full-time employees of Pfizer at the time the study was completed and hold stock and/or stock options in Pfizer.
  
  
  
  The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This study was sponsored by Pfizer, which was involved in the study design, the collection, analysis, and interpretation of the data, the writing of the report, and the decision to submit the paper for publication. Medical writing support was provided by Penny Gorringe, MSc, of Engage Scientific Solutions and funded by Pfizer.
authors.affiliation: Pfizer Inc, Global Innovative Pharma Business, Clinical Pharmacology, Groton, CT, USA Peter.Lockwood@pfizer.com.
authors.forename: Peter A
authors.initials: PA
authors.lastname: Lockwood
authors.affiliation: Pfizer Inc, Global Innovative Pharma Business, Clinical Sciences, Groton, CT, USA.
authors.forename: Lynne
authors.initials: L
authors.lastname: Pauer
authors.affiliation: Pfizer Inc, Global Innovative Pharma Business, Clinical Sciences, Groton, CT, USA.
authors.forename: Joseph M
authors.initials: JM
authors.lastname: Scavone
authors.affiliation: Pfizer Inc, Clinical Research Unit, Brussels, Belgium.
authors.forename: Maud
authors.initials: M
authors.lastname: Allard
authors.affiliation: Pfizer Inc, Clinical Research Unit, Brussels, Belgium.
authors.forename: Laure
authors.initials: L
authors.lastname: Mendes da Costa
authors.affiliation: Pfizer Inc, Global Innovative Pharma Business, Clinical Assay Group, Groton, CT, USA.
authors.forename: Tanja
authors.initials: T
authors.lastname: Alebic-Kolbah
authors.affiliation: Pfizer Inc, Global Innovative Pharma Business, Clinical Statistics, Collegeville, PA, USA.
authors.forename: Anna
authors.initials: A
authors.lastname: Plotka
authors.affiliation: Pfizer Inc, Global Innovative Pharma Business, Pharmacometrics, Groton, CT, USA.
authors.forename: Christine W
authors.initials: CW
authors.lastname: Alvey
authors.affiliation: Pfizer Inc, Global Innovative Pharma Business, Clinical Pharmacology, Groton, CT, USA.
authors.forename: Marci L
authors.initials: ML
authors.lastname: Chew
keywords: breastfeeding; lactation; pregabalin